Lactobacillus salivarius

Lactobacillus salivarius (Ligilactobacillus salivarius under the 2020 taxonomic revision) is a homofermentative species native to the human oral cavity, intestinal tract, and breast milk. The species is notable for the production of broad-spectrum bacteriocins active against gram-positive and selected gram-negative organisms.

Supplied as a freeze-dried powder with viability between 100 and 500 billion CFU per gram at release. The species tolerates gastric acid and bile salts and demonstrates strong adhesion to oral and intestinal epithelial surfaces.

Off-white to pale beige free-flowing powder with a clean fermented note. Particle size suitable for capsule, sachet, chewable tablet, and oral lozenge formats.

We supply food-grade Lactobacillus salivarius from manufacturers in China holding ISO 22000, FSSC 22000, Halal, Kosher, and other certifications relevant to probiotic strain production.

Common market grades include 100, 200, and 500 billion CFU per gram freeze-dried powders, lozenge-ready blends for oral health applications, and microencapsulated versions for beverage and capsule formats. Bulk and reduced-MOQ shipments with batch-level COA covering viable count, strain identity, moisture, heavy metals, and pathogen panel.

Lactobacillus salivarius was originally isolated from human saliva and first formally described in 1953. Reference strains include ATCC 11741 and the commercial strain UCC118, isolated at University College Cork and extensively studied in the context of bacteriocin production and inflammatory bowel disease models.

Industrial production uses MRS-based proprietary media under anaerobic conditions, followed by centrifugal harvest, cryoprotectant blending, and lyophilization to residual moisture below 5 percent. Strain identity is verified by 16S rRNA sequencing and bacteriocin gene cluster confirmation.

Regulatory status includes GRAS notifications with FDA for specific strains, Qualified Presumption of Safety listing in the European Union, and approval for use in functional food and infant formula applications in selected regions.

Clinical evidence supports use in oral health (reduction of plaque and gingivitis markers), inflammatory bowel disease symptom modulation, and immune function. The bacteriocin-producing phenotype underpins the species position in antimicrobial-focused probiotic formulations.

• Oral health lozenges, chewable tablets, and toothpaste applications
• Probiotic capsules and tablets for digestive health
• Women's health and lactation support supplements
• Functional dairy and fermented beverages
• Pediatric probiotic sachets and drops
• Halitosis and gingivitis support formulations
• Multi-strain probiotic stacks for immune support
• Animal feed and pet food probiotic premixes
• Synbiotic formulations with prebiotic fibers